Hemorrhoidal disease, pathology of the tissue lining the anal canal, affects approximately 10 million individuals in the US. Author Jean H. Ashburn, MD, of Wake Forest University School of Medicine and JAMA Senior Editor Karen E. Lasser, MD, MPH, discuss the current evidence on the epidemiology, pathophysiology, diagnosis, and treatment of hemorrhoidal disease. Related Content: Hemorrhoidal Disease ----------------------------------- JAMA Editors' Summary
-------- Â
18:40
--------
18:40
Treatment of Complicated Staphylococcus aureus Bacteremia
Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content: Dalbavancin for Treatment of Staphylococcus aureus Bacteremia Management of Staphylococcus aureus Bacteremia ----------------------------------- JAMA Editors' Summary
-------- Â
11:35
--------
11:35
Diagnosis and Management of Prostatitis
Prostatitis affects approximately 9.3% of men in their lifetime and includes acute and chronic bacterial infection and nonbacterial chronic prostatitis with chronic pelvic pain syndrome. Author Minh N. Pham, MD, from University of North Carolina School of Medicine discusses this and more with JAMA Deputy Editor Mary M. McDermott, MD. Related Content: Prostatitis ----------------------------------- JAMA Editors' Summary
-------- Â
17:51
--------
17:51
Geroscience in Medicine
Geroscience aims to define and modify biologic pathways associated with aging and age-related diseases. Author Stephen B. Kritchevsky, PhD, of the Wake Forest University School of Medicine and JAMA Deputy Editor Mary M. McDermott, MD, discuss current evidence regarding geroscience, human health, and promising therapies that may slow aging and age-related decline. Related Content: Geroscience ----------------------------------- JAMA Editors' Summary
-------- Â
16:23
--------
16:23
Managing Adverse Effects of Obesity Medications
New medications for obesity, such as semaglutide and tirzepatide, are highly effective but can be associated with adverse effects that reduce adherence. Obesity expert and author Robert Kushner, MD, joins JAMA Deputy Editor Mary McDermott, MD, to discuss a recent JAMA Insights article on managing adverse effects of obesity medications. Related Content: Managing Adverse Effects of Incretin-Based Medications for Obesity ----------------------------------- JAMA Editors' Summary
Ireland